


Chakraborty et al
B Cell FcγRIIb and Atherosclerosis
Supplemental Material


Supplemental Figure I

Pre-gated on Fsc/SSc
and Live/Dead staining




Supplemental Figure I. Gating strategies used in flow cytometry. In some experiments, GC B cells were gated as B220⁺ IgM⁺ CD95⁺ GL7⁺. B1 cells are additionally CD19⁺ IgM⁺ B220^{lo}.

Supplemental Figure II




Supplemental Figure II. A-D. Analysis of *Ldlr*^{-/-} chimeric mice transplanted with WT control or B^{tg} bone marrow after 6 weeks western diet. **A.** Proportion of B cells expressing high levels of Fas (CD95^{hi} GL7⁻). **B.** Serum total cholesterol. **C.** Body weight. **D.** Blood monocyte subsets (CD11b⁺ Ly6G⁻ CD115⁺ and Ly6C lo, int or hi) and neutrophils (CD11b⁺ Ly6G⁺). **E-H.** Analysis of *Ldlr*^{-/-} chimeric mice transplanted with WT control or FcγRIIb-macrophage transgenic (M^{tg}) bone marrow after 6 weeks western diet. **E.** Mean fluorescent intensity for FcγRIIb on B cells and CD11b⁺ cells. **F.** Atherosclerotic plaque area. **G.** Macrophage (MOMA2)-positive area of plaque. **H.** Serum total cholesterol.

Supplemental Figure III




Supplemental Figure III. A-D. Analysis of $Apoe^{-/-}$ or B^{tg} $Apoe^{-/-}$ mice after 6 or 12 weeks western diet. **A.** Atherosclerosis quantified using Oil Red O-stained aortic root cryosections. **B.** Serum total cholesterol. **C.** Body weight. **D.** Blood monocyte subsets (CD11b⁺ Ly6G⁻ CD115⁺ and Ly6C^{lo}, int or hi) and neutrophils (CD11b⁺ Ly6G⁺). **E.** Total cell numbers in spleens from each B^{tg} cohort. **F.** Bone marrow cell numbers in $Apoe^{-/-}$ or B^{tg} $Apoe^{-/-}$ mice after 6 or 12 weeks western diet. **G-J.** Analysis of atherosclerotic plaques for proportions of positive staining for MOMA2 (G), α -SMA (H), necrotic core (I) or collagen (J) in aortic roots from $Apoe^{-/-}$ or B^{tg} $Apoe^{-/-}$ mice after 12 weeks western diet.

Supplemental Figure IV




Supplemental Figure IV. A+B. Levels of plaque CD3⁺ T cells in aortic roots from *Ldlr*^{-/-} chimeric mice transplanted with WT control or B^{tg} bone marrow after 6 weeks western diet (A) or *Apoe*^{-/-} or B^{tg} *Apoe*^{-/-} mice after 12 weeks western diet (B). **C-D.** Proportion of spleen effector memory CD4⁺ T cells (CD3⁺ CD4⁺ CD62L⁻ CD44^{hi}) in *Ldlr*^{-/-} chimeric mice transplanted with WT control or B^{tg} bone marrow after 6 weeks western diet (C) or *Apoe*^{-/-} or B^{tg} *Apoe*^{-/-} mice after 12 weeks western diet (D). **E.** Serum BAFF levels in *Ldlr*^{-/-} chimeric mice transplanted with WT control or B^{tg} bone marrow after 6 weeks western diet. **F-J.** Serum antibody titres in *Ldlr*^{-/-} chimeric mice transplanted with WT control or B^{tg} bone marrow after 6 weeks western diet.

Supplemental Figure V




Supplemental Figure V. A-F. Analysis of male *FcγRIIb*^{BL6} *Apoe*^{-/-} (BL6) or *FcγRIIb* ^{Δ AP-1} *Apoe*^{-/-} (Δ AP-1) mice after 6 weeks western diet. Proportions of spleen B cell subsets (see figure S1). **B.** Follicular helper T cells (CD3⁺ CD4⁺ PD-1^{hi} CXCR5^{hi}). **C.** Body weights. **D.** Serum total cholesterol. **E.** Blood monocytes subsets (CD11b⁺ Ly6G⁻ CD115⁺ and Ly6C lo, int or hi) and neutrophils (CD11b⁺ Ly6G⁺). **F.** Plaque CD3⁺ Cells. *p<0.05.

Supplemental Figure VI



Supplemental Figure VI. A. B1 cells purified from peritoneum of *Apoe*^{-/-} or B^{tg} *Apoe*^{-/-} mice were cultured for 16h with or without anti-FcγRIIB (2.4G2 antibody) then stained with annexin V and propidium iodide. Absolute numbers of remaining live cells (AnnV⁻ PI⁺) was quantified by flow cytometry using beads for normalization. **B.** Necrotic core area in aortic root plaques from female *Apoe*^{-/-} or B^{tg} *Apoe*^{-/-} mice after 6 weeks western diet. **C.** FcγRIIb levels on Spleen B1 cells in male and female *Apoe*^{-/-} or B^{tg} *Apoe*^{-/-} mice. **D.** IgM clearance rates determined after transfer of IgM^a serum (from Balb/c mice) into male or female *Apoe*^{-/-} mice (each gender received gender matched serum). **E.** Mean spot size of IgM-secreting spleen cells from male and female *Apoe*^{-/-} mice analysed by Elispot. Representative experiment of more than 5.

Supplemental Figure VII



Supplemental Figure VII. A-E. Analysis of *Apoe*^{-/-} or *FcγRIIb*^{ΔAP-1} *Apoe*^{-/-} female mice after 6 weeks western diet. **A.** Mean fluorescence intensity (MFI) of anti-FcγRIIb staining on follicular (FO) or germinal center (GC) B cells from *Apoe*^{-/-} or *FcγRIIb*^{ΔAP-1} *Apoe*^{-/-} female mice. **B.** Spleen GC B cell levels. **C.** Total serum IgG2c. **D.** Total IgM levels. **E.** Atherosclerotic plaque area. N=6/group. *p<0.05. **F-H.** Comparison of male and female *Apoe*^{-/-} mice. **F.** Follicular helper T cells. **G.** Anti-dsDNA IgG antibodies. **H.** Total IgG2c.

Supplemental Table I

Target	Clone	Company
Ly6C	7/4	AbD Serotec
Ly-6G	1A8	BD
CD95 (Fas)	Jo2	BD
CD11b	M1/70	Biolegend
CD11c	N418	Biolegend
CD16.2	9E9	Biolegend
CD43	Ly48 gp115	Biolegend
CD44	1M7	Biolegend
CD62L	MEL-14	Biolegend
CD138	281-2	Biolegend
CD3	145-2C11	Biolegend
CD19	6D5	Biolegend
CXCR5	L138D7	Biolegend
PD-1	4B12	Biolegend
CD23	B3B4	Biolegend
CD16/32	93	Biolegend
MHCII	M5/114.15.2	Biolegend
B220	RA3-6B2	Life Tech.
CD4	RM4-5	Life Tech.
IgM	II/41	Life Tech.
GL7	GL7	Life Tech.
CD21	4E3	Life Tech.
CD115	AFS98	Life Tech.
Ki67	SolA15	Life Tech.
CD64	REA286	Miltenyi

Supplemental Table II - Summary of effects of B cell FcγRIIB models on major parameters

<i>FcγRIIb</i> <i>mutation</i>	FcγRIIB^{Btg} <i>(increased FcγRIIB on B cells)</i>			FcγRIIB^{ΔAP-1} <i>(decreased FcγRIIb on GC B Cells)</i>	
<i>Model</i>	<i>Ldlr^{-/-}</i>	<i>ApoE^{-/-}</i>		<i>ApoE^{-/-}</i>	
<i>Gender</i>	<i>Male</i>	<i>Male</i>	<i>Female</i>	<i>Male</i>	<i>Female</i>
Parameter:					
Plasma Cells	n.d.	↓	↓*	↔	↔*
GC B Cells	n.d.	↓	↓*	↑	↔
B1 Cells	↔*	↔	↓	↔	↔*
IgG2c	↓	↓	↓*	↑	↔
IgG1	↓	↓	↓*	↔	↔*
IgM	↔	↔	↓	↑	↔*
Teff	↓	↓	↓*	↔	↔*
Atherosclerosis	↓	↓	↑	↑	↔

*Data not shown.